Evidence map›Paper›PMID 42643428›Full record

ArticleFrontiers in pharmacology2026

Sangita Dey, Khushbu Wadhwa, Neha Kumari, Chetan Pandey, Anoop Kumar, Vincenzo Calderone, Simone Brogi, Neha Kapoor

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sangita Dey *Department of Biotechnology, North Bengal University, Darjeeling, West Bengal, India.
Khushbu Wadhwa *Fungal Biology Laboratory, Ramjas College, University of Delhi, Delhi, India.
Neha Kumari *Chemical Biology Lab, Hindu College, University of Delhi, Delhi, India.
Chetan Pandey *Chemical Biology Lab, Hindu College, University of Delhi, Delhi, India.
Anoop KumarDepartment of Biotechnology, North Bengal University, Darjeeling, West Bengal, India.
Vincenzo CalderoneDepartment of Pharmacy, University of Pisa, Pisa, Italy.
Simone BrogiDepartment of Pharmacy, University of Pisa, Pisa, Italy.
Neha KapoorChemical Biology Lab, Hindu College, University of Delhi, Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic hormonal imbalances and associated symptoms characterize ovarian cancer. PARP-1 inhibitors, such as olaparib and ruparib, are used to treat it, but new drugs are needed to overcome toxicity and resistance issues. PARP inhibition in Methods: We synthesized silver nanoparticles (AgNPs) from Results: Discussion: The anticancer properties of AgNPs from

Indexed as

anticancernanotechnologyovarian cancerPARP proteinphytochemicalssilver nanoparticles (AgNPs)

Identifiers

PMID42643428
PMCPMC13503321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.